Gilad Oren 4
4 · Aprea Therapeutics, Inc. · Filed Feb 2, 2026
Research Summary
AI-generated summary of this filing
Aprea Therapeutics (APRE) CEO Gilad Oren Buys Shares, Gets Warrants
What Happened
Gilad Oren, President, CEO and a director of Aprea Therapeutics (APRE), participated in a private placement that closed January 30, 2026. He acquired 28,100 shares of common stock at $0.89 per share for a cash outlay of $25,009 and also received common warrants to purchase up to 28,100 additional shares (warrants reported as a derivative acquisition).
Key Details
- Transaction date: January 30, 2026; Form 4 filed February 2, 2026.
- Common stock purchase: 28,100 shares @ $0.89 per share = $25,009.
- Derivative received: Common warrants to purchase up to 28,100 shares (no separate exercise price reported on the Form 4 line).
- Ownership after transaction: Not specified in the provided filing.
- Notable footnotes:
- F1: Reporting person disclaims beneficial ownership of these securities.
- F2: Shares and accompanying warrants were issued in a private placement under a securities purchase agreement dated Jan 28, 2026.
- F3: Warrants are immediately exercisable but subject to ownership caps (cannot be exercised if doing so would push beneficial ownership above 4.99% or combined voting power above 9.99%).
- F4: Warrants expire by the second anniversary of the earlier of registration effectiveness for the underlying shares or eligibility for sale under Rule 144 (with certain conditions).
- Filing timeliness: Report filed Feb 2, 2026 reporting the Jan 30, 2026 transaction; no late-filing flag indicated.
Context
This was a purchase in a private placement (a cash purchase of common stock plus warrants). Purchases by insiders are often of interest to retail investors as a straightforward sign of insider buying activity; the warrants add potential upside if exercised later but carry exercise and ownership-limit conditions. The filing includes a disclaimer of beneficial ownership (F1), and the warrants are subject to ownership caps and an expiration window described above.
Insider Transaction Report
- Purchase
Common Stock
[F2]2026-01-30$0.89/sh+28,100$25,009→ 373,720 total - Purchase
Common Warrant
[F3][F4]2026-01-30+28,100→ 28,100 totalExercise: $0.77From: 2026-01-30→ Common Stock (28,100 underlying)
- 1,200(indirect: By Daughter)
Common Stock
[F1] - 600(indirect: By Son)
Common Stock
[F1]
Footnotes (4)
- [F1]The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- [F2]On January 28, 2026, the Issuer entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement, which closed on January 30, 2026, an aggregate of 28,100 shares of the Issuer's common stock (the "Shares") at a purchase price of $0.89 per Share. The Reporting Person also received accompanying common warrants (the "Common Warrants") to purchase up to an aggregate of 28,100 Shares.
- [F3]The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise.
- [F4]The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the second year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144.